Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?

Table 1

Principal papers which focused on the role of genotypes and possible neonatal outcomes.

Laine et al., 2004 [20]	32-year-old woman SSRI exposed	Chlorpromazine,; paroxetine	Genetic analysis: CYP2D6*4 mutation in both alleles = poor metabolizer; APGAR 7/8/9; Poorly reactive, respiratory distress, tremors, hypotonia, and hypoglycemia
Oberlander et al., 2008 [19]	37 women SSRI exposed versus 47 nonexposed	Paroxetine, fluoxetine, sertraline, venlafaxine, citalopram	SS alleles: lower 5 min APGAR score (reduced respiratory effort); LL alleles: lower birth weight
Hilli et al., 2009 [22]	20 women SSRI exposed during pregnancy and lactation	Citalopram; Fluoxetine	No differences between 5HTT and 5HT receptors genotypes and serotoninergic symptoms scores.; Higher scores in infants with two high activity alleles of the MAO-A polymorphism and rapid CYP2DS metabolizers.